Search hospitals > Alabama > Mobile
Mobile Infirmary Medical Center
Claim this profileMobile, Alabama 36607
Global Leader in Skin Cancer
Global Leader in Breast Cancer
Conducts research for Colorectal Cancer
Conducts research for Lung Cancer
Conducts research for Head and Neck Cancers
89 reported clinical trials
8 medical researchers
Summary
Mobile Infirmary Medical Center is a medical facility located in Mobile, Alabama. This center is recognized for care of Skin Cancer, Breast Cancer, Colorectal Cancer, Lung Cancer, Head and Neck Cancers and other specialties. Mobile Infirmary Medical Center is involved with conducting 89 clinical trials across 154 conditions. There are 8 research doctors associated with this hospital, such as Kannan Thanikachalam, Furhan Yunus, John R. Russell, and Jan O. Kemnade.Area of expertise
1Skin Cancer
Global Leaderp16 positive
HER2 positive
Stage IV
2Breast Cancer
Global LeaderHER2 positive
ER positive
ER negative
Top PIs
Kannan ThanikachalamThomas Hospital4 years of reported clinical research
Studies Pancreatic Cancer
Studies Gastroesophageal Junction Adenocarcinoma
5 reported clinical trials
16 drugs studied
Furhan YunusMobile Infirmary Medical Center3 years of reported clinical research
Studies Skin Cancer
Studies Cancer
4 reported clinical trials
25 drugs studied
John R. RussellMobile Infirmary Medical Center7 years of reported clinical research
Studies Gastroesophageal Junction Adenocarcinoma
Studies Prostate Cancer
4 reported clinical trials
13 drugs studied
Jan O. KemnadeMichael E DeBakey VA Medical Center3 years of reported clinical research
Studies Cancer
Studies Skin Cancer
3 reported clinical trials
6 drugs studied
Clinical Trials running at Mobile Infirmary Medical Center
Breast Cancer
Cutaneous Melanoma
Breast cancer
Melanoma
Skin Cancer
Squamous Cell Carcinoma
Pancreatic Cancer
Stroke
Adenosquamous Carcinoma
Pancreatic Carcinoma
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
T-DM1 + Tucatinib
for Breast Cancer
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Mobile Infirmary Medical Center?
Mobile Infirmary Medical Center is a medical facility located in Mobile, Alabama. This center is recognized for care of Skin Cancer, Breast Cancer, Colorectal Cancer, Lung Cancer, Head and Neck Cancers and other specialties. Mobile Infirmary Medical Center is involved with conducting 89 clinical trials across 154 conditions. There are 8 research doctors associated with this hospital, such as Kannan Thanikachalam, Furhan Yunus, John R. Russell, and Jan O. Kemnade.